Aptevo Therapeutics
16.7.2021 14:06:46 CEST | ACCESS Newswire | Press release
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that Dr. Jane Gross, Senior Vice President of Research and Development and Chief Scientific Officer of Aptevo, will give a presentation and participate in a live interactive panel discussion at the Cambridge Health Institute PEGS Virtual Conference being hosted from Monday, July 19, 2021 - Thursday, July 22, 2021.
Dr. Gross' talk, entitled "Generating Immuno-Modulatory Bispecific Therapeutic Candidates for the Treatment of Hematologic and Solid Tumors," will occur on Monday, July 19, 2021 at 11:25 am Eastern time. This presentation will focus on those aspects that are unique to the Aptevo ADAPTIR and ADAPTIR-FLEX platforms and enable the generation of bispecific and multi-specific therapeutic candidates with anti-cancer potential.
The live, interactive panel session, to include Dr. Gross and entitled "Bispecifics vs CAR T Therapy for T Cell Engagement: Competing or Complementary?" will occur on Monday, July 19, 2021 at noon Eastern time. The panel discussion will focus on the benefits of bispecific antibodies vs. CAR T therapies and the potential role of either or both treatment modalities for the treatment of cancers.
"We are excited about Jane's participation in the upcoming PEGS conference because it provides an important platform from which we can share the accomplishments and potential of our ADAPTIR and ADAPTIR-FLEX technologies," said Marvin White, President and CEO of Aptevo. "There is a growing body of evidence that tells us the fight against cancer will require many kinds of therapies that are both cancer specific and patient specific. Robust discussion around these needs, and the relative benefits and challenges associated with them, is critical to our collective success."
About Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein platform technology. APVO442 was developed based on the new ADAPTIR-FLEX™ platform technology. The ADAPTIR and ADAPTIR-FLEX platforms are capable of generating highly differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. Aptevo is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on difficult to treat forms of cancer. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and safety of its therapeutic candidates and potential use of any such candidates as therapeutics for treatment of disease, advancement of its clinical trials and its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "optimism," "potential," "designed," "engineered," "breakthrough," "innovative," "innovation," "promising," "plans," "forecasts," "estimates," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and enrollment of future clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, actions of activist stockholders, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19). These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.
CONTACT:
Investors or Media
Miriam Weber Miller
Head, Investor Relations & Corporate Communications
Email: millerm@apvo.com or IR@apvo.com
Phone: (206) 859-6628
SOURCE: Aptevo Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/655758/Aptevo-Therapeutics-Chief-Scientific-Officer-Jane-Gross-PhD-to-Present-at-Upcoming-Cambridge-Health-Institute-PEGS-Virtual-Conference
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Expands European Compliance Market Capabilities With Spanish EU ETS Registry Account9.7.2026 16:00:00 CEST | Press release
Milestone Strengthens Karbon-X's European Regulatory Infrastructure and Expands Its Operational Capabilities Within the World's Largest Compliance Carbon Market CALGARY, AB / ACCESS Newswire / July 9, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced the establishment of its European Union Emissions Trading System (EU ETS) Registry Account in Spain following regulatory approval from Spain's Office for Climate Change (Oficina Española de Cambio Climático). The milestone further strengthens the Company's regulatory infrastructure in Europe and marks another step in the continued execution of its European growth strategy. Following regulatory approval, the Company's EU ETS Registry Account has been established within the Spanish section of the Union Registry. Final technical activation by the Spanish Registry (RENADE) is expected shortly, aft
Parents Are Underestimating Their Kids' Digital Lives - Especially With AI: New Family Online Safety Institute Research9.7.2026 16:00:00 CEST | Press release
Survey of 4,000+ U.S. and Australian families finds children report doing more online - from social media to generative AI - than their parents realize. WASHINGTON, D.C. / ACCESS Newswire / July 9, 2026 / The Family Online Safety Institute (FOSI) today released Beyond Borders: U.S. and Australian Families on Online Safety, Screen Use, and the Digital Lives of Kids, the fourth wave of its bi-annual Online Safety Survey. When asked whether their child had used generative AI in the past week, 27% of parents said yes. When children were asked the same question about themselves, 38% said yes, an 11-point gap. The pattern held across nearly every online activity measured, including scrolling social media (46% of parents vs. 54% of children) and posting on social media (30% vs. 38%). Fielded in spring 2026 by Ipsos with more than 4,000 parents and children ages 10-17 across the United States and Australia, the research reveals a consistent and significant gap: children report doing more onlin
Haier Europe Appoints Stagwell (STGW) as Creative Agency for the Haier Brand, Following Ingenuity+ Pitch Process9.7.2026 09:35:00 CEST | Press release
LONDON, GB / ACCESS Newswire / July 9, 2026 / Today, Haier Europe appoints Stagwell (NASDAQ:STGW), the challenger network transforming marketing through AI, as its lead creative agency for the Haier Brand, following a competitive pitch process managed by Ingenuity+. Haier strives to deliver premium appliances powered by intelligent technology, naturally designed around customers, empowering them every day as their needs evolve. Stagwell was selected to support the Haier brand through its next phase of growth, bringing its "More Creation, More Possibilities" brand payoff to life through creative communications across Europe. Coordinated by a Client Service Team based in the Italian office, Stagwell will lead creative strategy and campaign development, helping the Haier brand in Europe to translate its vision into a consumer-relevant communication platform across markets and product lines. Stagwell's digital agency, Assembly Digital Commerce, will support with content for online and e-co
Karbon-X Announces Strategic Partnership to Evaluate Kenya BioHub Initiative8.7.2026 15:00:00 CEST | Press release
Company to conduct feasibility assessment for integrated land restoration and renewable energy initiative as part of its strategy to expand its international climate project development pipeline. CALGARY, AB / ACCESS Newswire / July 8, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company delivering end-to-end services across global carbon markets and climate infrastructure, today announced a strategic partnership with REGID International ("REGID") to jointly evaluate the Kenya BioHub Initiative, an integrated climate infrastructure program designed to restore degraded land, produce sustainable biomass, and support industrial decarbonization in Kenya. The partnership reflects Karbon-X's disciplined approach to identifying, evaluating, and selectively advancing climate infrastructure opportunities with long-term development potential as part of its strategy to expand its international project development pipeline. The Kenya B
Frame Security Launches KnowBetter as AI Reshapes Social Engineering8.7.2026 14:00:00 CEST | Press release
AI Is Rewriting the Social Engineering Playbook. Security Awareness Training Hasn't Caught Up. Organizations must KnowBetter. NEW YORK CITY, NY / ACCESS Newswire / July 8, 2026 / Security teams have spent two decades training employees to spot a familiar set of red flags: a suspicious link, a misspelled domain, an urgent request for a wire transfer. That approach is now colliding with an attacker toolkit that has changed faster than most awareness programs have. Generative AI has made it possible to clone a voice from a few seconds of audio, generate a passable deepfake video in minutes, and write a phishing email tailored to a specific employee's role, manager, and recent LinkedIn activity. Vishing calls, smishing texts, and video-based impersonation are now standard components of enterprise social engineering campaigns, not edge cases. "Most organizations are still training people to recognize threats from five years ago," said Tal Shlomo, co-founder and CEO of Frame Security, a huma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom